Cargando…
Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib
BACKGROUND: There has been a recent surge in interest in predicting biological effects associated with genomic alterations in order to implement personalized cancer treatment strategies. However, no reports have yet evaluated the utility of profiling blood-based circulating tumor DNA (ctDNA) in hepa...
Autores principales: | Fujii, Yasutoshi, Ono, Atsushi, Hayes, C. Nelson, Aikata, Hiroshi, Yamauchi, Masami, Uchikawa, Shinsuke, Kodama, Kenichiro, Teraoka, Yuji, Fujino, Hatsue, Nakahara, Takashi, Murakami, Eisuke, Miki, Daiki, Okamoto, Wataru, Kawaoka, Tomokazu, Tsuge, Masataka, Imamura, Michio, Chayama, Kazuaki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235843/ https://www.ncbi.nlm.nih.gov/pubmed/34174931 http://dx.doi.org/10.1186/s13046-021-02016-3 |
Ejemplares similares
-
Early changes in ammonia levels and liver function in patients with advanced hepatocellular carcinoma treated by lenvatinib therapy
por: Ohya, Kazuki, et al.
Publicado: (2019) -
Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma
por: Yamauchi, Masami, et al.
Publicado: (2020) -
Lenvatinib activates anti-tumor immunity by suppressing immunoinhibitory infiltrates in the tumor microenvironment of advanced hepatocellular carcinoma
por: Yamauchi, Masami, et al.
Publicado: (2023) -
Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib
por: Ono, Atsushi, et al.
Publicado: (2020) -
Levocarnitine Use Is Associated With Improvement in Sarcopenia in Patients With Liver Cirrhosis
por: Hiramatsu, Akira, et al.
Publicado: (2019)